Skip to main content
LTRN
NASDAQ Life Sciences

EMA Clears Lantern's LP-184 Trial in Biomarker-Selected Bladder Cancer

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.84
Mkt Cap
$35.597M
52W Low
$1.11
52W High
$5.744
52W Position info
156% above low
Off High info
51% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

LTRN has more than doubled off its 52-week low of $1.11 on light trading volume (0.2× avg).

Summary

Lantern Pharma received EMA clearance to start an investigator-initiated Phase 1b/2 trial of LP-184 (zirdafulven) in advanced bladder cancer. The study will enroll up to 39 patients at Rigshospitalet in Copenhagen, using a dual biomarker strategy to select those most likely to respond. This is the first clinical trial for LP-184 in bladder cancer, expanding the drug's pipeline beyond the ongoing glioblastoma and other solid tumor programs. The news follows a series of positive developments, including favorable FDA feedback on the LP-300 HARMONIC trial and a recent capital raise, but the company's cash runway remains limited. A clinical signal here could open a large market opportunity in later-line urothelial carcinoma, where effective options are scarce.

At the time of this announcement, LTRN was trading at $2.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.6M. The 52-week trading range was $1.11 to $5.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

LTRN - Latest Insights

LTRN
Nov 18, 2026, 8:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.3724
Real-time Price: $0.3601 info
Change: -$0.0123 (-3%) info
Market Cap: $5.377M info
LTRN
Nov 18, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3724
Real-time Price: $0.3601 info
Change: -$0.0123 (-3%) info
Market Cap: $5.377M info
LTRN
Nov 17, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.365
Real-time Price: $0.3601 info
Change: -$0.0049 (-1%) info
Market Cap: $5.377M info
LTRN
Oct 08, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.830
Real-time Price: $0.3601 info
Change: -$0.4699 (-57%) info
Market Cap: $5.377M info
LTRN
Oct 07, 2026, 8:31 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.3601 info
Change: -$0.5899 (-62%) info
Market Cap: $5.377M info